Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Not sure what you are 'concerned' about, but I would be asking about the POTENTIAL REVENUE stream..
And ponder, how many 'units' of product will the market DEMAND/NEED.. and how much could they sell it for...
et al.. Thats the part that I am looking for clarification on as it will help guide the 'target price'..
Right now, its running on expectations, momentum.. Which is more than ok as it gets off the 'floor'.
Course, at this point, ANY additional sales would be a positive..
And Sam Bankman-Fried knew a lot about bitcoin too just saying….
Jagx has a board of certified doctors
Common sense would tell me if anyone in the house is a doctor or knows of a doctor if they could get back to all of us who are non-medical and see if this is really legit or what their thoughts are thanks!!!
$JAGX another huge week coming up .
Just hope we all just not drinking the kool-Aid… no way been daytrading for 20 years ALLL SIGNS POINT UP!!!!!
Check this video I saw on TikTok https://www.tiktok.com/t/ZTLCL6C7W/
Gotcha… PR comes out what we all waiting for and they have until Aug this year to get to $1.00 or RS coming once again
The point was they jump in on moving stocks with volume. JAGX already had the volume and moving.
They added to the volume buying and then the selling and shorting. And repeating
Over the last year JAGX was on alerts a few times.
Probably all of Tim Sykes and his little minions pulling out for the week to get their beer money
Pull up any 1 or 2 year chart look at volume and Green Day’s recently HUGE MOMO play!
Apparently we need AI programs not Tim lol
I Just got this TimSykes email
This 10 cent stock DOUBLED in 1 day
On April 15th, Jaguar Health (JAGX) was trading for around $0.10 cents per share.
Because it’s a penny stock, no one was paying attention to it.
But our new AI system sensed a BIG move coming…
So the AI sent out an immediate buy signal.
And sure enough…
Just 1 day later…
JAGX ripped from $0.10 cents to $0.25 cents for an ultra fast 150% gain.
You might think that’s a “once in a blue moon” type of thing.
And you’d be right for most stocks.
For example, it took Nvidia the past 6 months to double in price, and that’s one of the fastest moving large caps in the market.
But for penny stocks like JAGX…
Doubling in price really fast is far more common than you’d think.
That’s why I absolutely love trading penny stocks, and will NEVER shut up about this strategy.
Because I’ve been able to turn $12.4k into over $7.6 Million career profits…
And I’ve helped 40 others become Millionaires too…
But if you want to learn our exact strategy…
Go here now to discover my simple secret to trading penny stocks that gain 150%+ in 1 day.
- Tim Sykes
?
?
66 West Flagler Street STE 900
Miami, Florida 33130
United States
Facebook Twitter Instagram YouTube
Click Here to Unsubscribe
1. Results are not typical. I teach methods that have made other traders money, but that does not guarantee you will make any money. Success in trading requires hard work and dedication. Past performance does not indicate future results. All trading carries risks.
**Timothy Sykes teaches skills others have used to make money. Any results displayed are extraordinary and are not typical and will vary from person to person. For more info read our Earning Claims Disclosure
About: Making money trading stocks takes time, dedication, and hard work. My goal is to teach you how I have succeeded in the market, but you may not achieve my results. Remember, there are risks involved with investing, including the potential loss of money.
We are strongly committed to protecting your privacy and providing a safe & high-quality online experience for all of our visitors. We understand that you care about how the information you provide to us is used and shared. We have developed a Privacy Policy to inform you of our policies regarding the collection, use, and disclosure of information we receive from users of our website.
Our Privacy Policy, along with our Term & Conditions, governs your use of this site. By using our site, or by accepting the Terms of Use (via opt-in, checkbox, pop-up, or clicking an email link confirming the same), you agree to be bound by our Terms & Conditions and our Privacy Policy.
If you have provided personal, billing, or other voluntarily provided information, you may access, review, and make changes to it via instructions found on the Website or by replying to this email. To manage your receipt of marketing and non-transactional communications, you may unsubscribe by clicking the “unsubscribe” link located on the bottom of any marketing email. Emails related to the purchase or delivery of orders are provided automatically – Customers are not able to opt out of transactional emails. We will try to accommodate any requests related to the management of Personal Information in a timely manner. However, it is not always possible to completely remove or modify information in our databases (for example, if we have a legal obligation to keep it for certain timeframes, for example).
If you have any questions, simply reply to this email or visit our website to view our official policies.
**
JAGX..........................................https://stockcharts.com/h-sc/ui?s=JAGX&p=W&b=5&g=0&id=p86431144783
Actually huge dump from the high!!!!
JAGX chart looks like a Nike swoosh symbol about to form a bowl Tcup whatever you wanna call it all points to positive. We can’t all be this stupid as investors says 141 milly shares traded that’s neat… battle again on Monday!!!!! Peace out!
JAGX is a great $$$$$ opportunity. So many positive fundamentals and technical indicators.
I was really excited about the quick rise to .36. I guess some profit takers for the weekend. Timber wolf must of had quick a few. Gave it a quite a dip at 11. But I’ll take a dime increase in one week. Maybe some big news next week.
Another green close tee hee :)
JAGX
POWER HOUR IN 47 minutes! Let’s see a strong close! Above .36!!!!
I thought this was just a flipping stock!!!?
That surge in volume out of nowhere wow JAGX setting up nicely for next week action 🚀
Market roaring, expecting 2 drops this year in the cards. LISA is very quiet... something big is coming :)
They don’t invest just to lose money….
Hedge Funds Weigh In On Jaguar Health
Hedge funds have recently made changes to their positions in the business. Citigroup Inc. bought a new position in shares of Jaguar Health in the first quarter worth about $34,000. Goldman Sachs Group Inc. boosted its stake in shares of Jaguar Health by 153.3% in the first quarter. Goldman Sachs Group Inc. now owns 54,770 shares of the biotechnology company’s stock worth $39,000 after acquiring an additional 33,148 shares during the period. Acadian Asset Management LLC bought a new position in shares of Jaguar Health in the first quarter worth about $43,000. Geode Capital Management LLC bought a new position in shares of Jaguar Health in the second quarter worth about $48,000. Finally, Bank of New York Mellon Corp lifted its position in shares of Jaguar Health by 507.3% in the first quarter. Bank of New York Mellon Corp now owns 169,749 shares of the biotechnology company’s stock worth $120,000 after buying an additional 141,796 shares in the last quarter. Institutional investors own 12.04% of the company’s stock.
Look at that volume
I think the last hour should be up, getting ready (collecting) for next week, imho
0.21... lol. I would consider myself lucky if i'll ever get a change of buying at 0.26. Today was close, but i wanted more, and look where it's now...*sigh*
Think all the predictions forgot to account for the RS…. lol
HOLY SHI_T NEW HIGHS COMING BOOOOOOOOOOOOOM
imho
123 milly shares not even NOON cst !!!! SOLID!
Looking good knrorrel!
Rolling the dice for another JAGXZEE 🎲 🎲 🎲 🎲 🎲
$JAGX
$JAGX 🔥🔥🔥🔥 just starting to move to new and higher levels and new highs 🚀🚀🚀
imo
$JAGX is about to go back up WOW BOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOM
No worries here the trend is our friend ➡️↗️
JAGX
If I hadn't had to do something this morn on the open, I would have taken the 33 cents plus. But decided to sell out when I got home at 30.25 cents/sh..
Why? 1. I bought it for the 'trade' in a take what it gives approach.
2. I wanted to be in for the PH 3 data release, but it got too chaotic again, too euphoric and they tend to 'pull back to an undetermined depth that is to be determined.
3. So took what it gave, and am watching. Note, when I sold my shares, they were 'taken' in very small lots vs all or nearly all of the shares going at once. Told me there was a lack of buyers when I sold to absorb them.
4. And see some buyers stepped in around 28 cents/sh. As is the norm in these pullbacks, there will be some that see it as cheap relative to where it 'just was (35 cents this morn) and put a pause in the pullback.
5. The unknown is how many buyers are there vs those holding wondering if they should take what it gave as well.
6. I plan to reload IF the price dips to 22 cents or less, ie, down where its CURRENT MOVING AVERAGE line is. I am a believer that the share price and its MA line like to get together and when they get too far apart, they get lonely and try to get together again.
and at the moment, the MA line for the time period I use is around 21 cents. So the question is, where will they decide to meet each other at now..
GOOD LUCK... again, I would like to own the shares again, but will be patient to see when that happens. And if I miss out, mis-read the strength of this move up from 12 cents (my first buy of shares), won't be the first time that happened.
Still a bit low for most people's average.
Don't worry, people need money for their weekend shopping and will sell in the last 10 minutes before the end of trading if JAGX starts to move up again.
lol
imho
6 times profits 600% I can not be more greedy I am out for real this time and good luck y’all
MANNNNN WONDER HOW MANY BUY ORDERS ARE PLACE AT OPENING...LOL....JAGX$$$$$$$$$$$
ANY MINUTE NOW B4 OPENING THEY GONNA SAY THE HELL WITH IT....I WANT IN!!!...WEVE ALL BEEN THERE.....JAGX$$$$$$$$$$$$$$$$$$$
Went almost to .37 and brought it down quickly. Don’t think they’ll be able to hold her down when the regular market opens! She’s about to blow!!!
LOOKS LIKE JAGX IS READY TO RIP AGAIN!!$$
Im amazed it didnt gap today but slow steady we go...Thanks for that solid DD :)
JAGX
Followers
|
151
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
6857
|
Created
|
12/01/15
|
Type
|
Free
|
Moderators ProfitChaser oldstocks DTGoody powerbattles crudeoil24 SmellMyFinger |
Jaguar Health, Inc. $JAGX
Bringing Plant-based Medicines to Life™
Pharmaceutical Manufacturing
San Francisco, California
Jaguar Health’s organizational framework is designed to enable our product pipeline to reach the world’s interconnected marketplace, allowing for development and commercialization opportunities worldwide.
Products:
Mytesi Crofelemer 125mg delayed release tablets
Mytesi is FDA-approved for symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy
Market size of the FDA HIV Mytesi Crofelemer could be $25-$30 Million in the USA
Mytesi has a novel mechanism of action that modulates chloride secretion in the gastrointestinal tract, reducing excessive chloride and accompanying water flow and relieving watery diarrhea.
Mytesi is not indicated for the treatment of infectious diarrhea. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (6%), bronchitis (4%), cough (4%), flatulence (3%), and increased bilirubin (3%).
Canalevia-CA1 Crofelemer delayed release tablets
Distributors listed:
https://www.canalevia.com/distributor-information
CANALEVIA-CA1 is conditionally approved for the treatment of chemotherapy-induced diarrhea (CID) in dogs.
Conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-552.
CAUTION: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian. It is a violation of Federal Law to use this product other than as directed in the labeling.
Lytham Partners Investor Select Conference February 1st, 2024
https://wsw.com/webcast/lytham10/jagx/2084640
Pipeline: https://jaguar.health/pipeline/
How to calculate the value of drugs and biotech companies
https://www.baybridgebio.com/drug_valuation.html
About the Jaguar Health Family of Companies
Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, and bowel incontinence.
Jaguar family company Napo Pharmaceuticals focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states.
Napo Pharmaceuticals' crofelemer drug product candidate is the subject of the OnTarget study, a pivotal Phase 3 clinical trial for preventive treatment of chemotherapy-induced overactive bowel (CIOB) in adults with cancer on targeted therapy.
Jaguar family company Napo Pharmaceuticals focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states.
Napo Pharmaceuticals' crofelemer drug product candidate is the subject of the OnTarget study , a pivotal Phase 3 clinical trial for preventive treatment of chemotherapy-induced overactive bowel (CIOB) in adults with cancer on targeted therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan and/or rare diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative is focused on developing novel prescription medicines derived from plants for mental health indications.
A Case Report: Improved Control of Tyrosine Kinase Inhibitor-Induced Diarrhea
Despite the efficacy of tyrosine kinase inhibitors (TKIs) across multiple cancers, side effects including treatment-related diarrhea can impede a patient’s ability to reach therapeutic doses or stay on therapy.
Below, we present the case of a 72-year-old patient with metastatic papillary renal cell carcinoma recurrent despite nephrectomy.
Over the course of treatment, the patient received multiple different tyrosine kinase inhibitors with varying efficacy.
Treatment with the TKI cabozantinib after failure of two prior TKIs resulted in a clinical response with shrinkage of his nodal metastatic disease.
However, the severe treatment-related diarrhea refractory to conventional management required both dose holds and dose reductions of cabozantinib.
Off-label administration of crofelemer, a novel FDA-approved antidiarrheal agent, successfully controlled the treatment-related diarrhea and allowed resumption and partial dose increase of cabozantinib.
This case suggests that crofelemer could be a viable therapeutic strategy to address TKI-induced diarrhea.
9.8 million people
receive chemotherapy worldwide per year
Wilson B, Jacob S, Yap M, et al. Estimates of global chemotherapy demands and corresponding physician workforce requirements for 2018 and 2040: a population-based study. Lancet Oncol. 2019;20(6):769-780. doi:10.1016/S1470-2045(19)30163-9
Chemotherapy-induced
diarrhea occurs in
50%-80%
of treated patients
Stein A, Voigt W, Jordan K. Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management. Ther Adv Med Oncol. 2010;2(1):51-63. doi:10.1177/1758834009355164
Patients with cancer therapy–
related diarrhea (CTD) were
40% more likely to
discontinue chemotherapy or
targeted cancer therapy than
patients without CTD
Okhuysen PC, Schwartzberg LS, Roeland E, et al. The impact of cancer-related diarrhea on changes in cancer therapy patterns. J Clin Oncol. 2021;39(15):12111. doi:10.1200/JCO.2021.39.15_suppl.12111
Research & Development
In October 2020, Napo Pharmaceuticals initiated a pivotal Phase 3 clinical trial
This Phase 3 study is evaluating crofelemer for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy
The principal investigator and co-investigators identified are from MD Anderson Cancer Center
Jaguar Health https://jaguar.health/
Napo Pharmaceuticals https://napopharma.com/
Napo Therapeutics https://napotherapeutics.com/en/
https://www.magdalenabiosciences.com/
Magdalena is a joint venture formed by Jaguar Health and Filament Health. The company holds an exclusive license to Jaguar's proprietary library of approximately 2,300 highly characterized medicinal plants and 3,500 plant extracts for designated therapeutic indications.
Visit Jaguar on LinkedIn:
https://www.linkedin.com/company/jaguar-health/
Visit Jaguar on Instagram: https://www.instagram.com/jaguarhealthcommunity/
Visit Jaguar on X: https://twitter.com/Jaguar_Health
Phone: 415-371-8300
Contact: hello@jaguar.health
Press Releases: https://jaguarhealth.gcs-web.com/news-releases
Most if not all works by mechanism chloride ions into the gut then water comes and diarrhea out. Crofelemer normalizes abnormal ion flow targeting only locally in the gut.
Jaguar has been putting the expense into making sure Crofelemer drug supply is ready to get into this opportunity to treat cancer related chemo patients since pharmacy’s already can get FDA approved, all ready in the in the supply chain in the pharmacy as Crofelemer for AIDs patients.
Research has shown it costs 3x as much to treat a cancer patient with diarrhea.
It would be better to treat the cancer patient for diarrhea with Crofelemer pending OnTarget Study and FDA approval.
Since Crofelemer is FDA approved to treat dogs for Cancer Chemo related Diarrhea it has been said:
If your going to have cancer and cancer related Diarrhea, it’s better to be a dog than a human right now.
The companies that manufacture the cancer agents/drugs sort of point to the availability of Crofelemer because it allows them to keep their patients on their therapies thereby improving their penetration and their revenues opportunity.
3rd party market research put Short Bowel Syndrome at $5-$12 Billion opportunity because these patience are so ill, high mortality, high morbidity (the state of being unhealth for a particular disease or situation), so high of expense to manage through life.
That opportunity can be reached in small trials around the world to show benefits to be able to show global development.
Product already approved, already fully in the supply chain in the pharmacy.
Potential Market of Mytesi (crofelemer)
Jaguar and Napo $JAGX if the Phase 3 OnTarget Study has good results.
The Phase 3 OnTarget Study results are due to be out soon in this quarter.
The Phase 3 OnTarget study is testing whether the company's plant-based prescription drug crofelemer can prevent or substantially reduce diarrhea and other symptoms of CIOB when any one of the selected 24 different targeted therapies that are associated with diarrhea in patients is initiated.
Each year, more than 1 million cancer patients in the United States receive chemotherapy or radiation. Globally 9.8 million require chemotherapy.
Diarrhea is a common side effect of targeted therapies. Up to 95% of patients on tyrosine kinase inhibitors (TKIs) suffer from diarrhea, depending on the TKI used.
Any drug used to treat cancer (including tyrosine kinase inhibitors or TKIs) can be considered chemo, but here chemo is used to mean treatment with conventional cytotoxic (cell-killing) drugs that mainly kill cells that are growing and dividing rapidly. Chemo was once one of the main treatments for CML.
The cost for Mytesi oral delayed release tablet 125 mg is around $2,600 for a supply of 60 tablets. This amount is the one month supply as testing in the OnTarget Study.
That is a 24 week study = 5.6 month supply needed = $14,560.00 for treatment.
Potential Market of Mytesi (crofelemer)
100,000 patients a year = $1,456,000,000
250,000 patients a year = $3,640,000,000
500,000 patients a year = $7,280,000,000
1,000,000 patients a year = $14,560,000,000 (assuming worldwide)
5,000,000 patients a year = $72,800,000,000 (assuming worldwide)
The estimate of patients depends on how many quit taking chemo, the onTarget Study, FDA approval and or quit taking Mytesi (crofelemer).
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |